Candel Therapeutics Inc Sustainability Reports
Candel Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies to fight cancer. The company utilizes genetically modified adenovirus and herpes simplex virus platforms to stimulate a systemic anti-tumor immune response in solid tumors.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00N0D4Z80
2 reports from 2023 to 2024
Company Profile
Candel Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies to fight cancer. The company utilizes genetically modified adenovirus and herpes simplex virus platforms to stimulate a systemic anti-tumor immune response in solid tumors.
Reports
2 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
